MA43409B1 - Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton - Google Patents

Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton

Info

Publication number
MA43409B1
MA43409B1 MA43409A MA43409A MA43409B1 MA 43409 B1 MA43409 B1 MA 43409B1 MA 43409 A MA43409 A MA 43409A MA 43409 A MA43409 A MA 43409A MA 43409 B1 MA43409 B1 MA 43409B1
Authority
MA
Morocco
Prior art keywords
kinase inhibitors
tyrosine kinase
polycyclic compounds
bruton tyrosine
compounds
Prior art date
Application number
MA43409A
Other languages
English (en)
Inventor
Nidhi Arora
Genesis M Bacani
Joseph Kent Barbay
Scott D Bembenek
Min Cai
Wei Chen
Charlotte Pooley Deckhut
James P Edwards
Brahmananda Ghosh
Kevin Kreutter
Gang Li
Mark S Tichenor
Jennifer D Venable
Jianmei Wei
John J M Wiener
Yao Wu
Kun Xiao
Feihuang Zhang
Yaoping Zhu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA43409B1 publication Critical patent/MA43409B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des composés de formule (i) à utiliser en tant qu'inhibiteurs de kinase de bruton et leur préparation, ainsi que des compositions comprenant lesdits composés.
MA43409A 2015-12-10 2016-12-09 Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton MA43409B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562265836P 2015-12-10 2015-12-10
PCT/US2016/065954 WO2017100662A1 (fr) 2015-12-10 2016-12-09 Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton

Publications (1)

Publication Number Publication Date
MA43409B1 true MA43409B1 (fr) 2020-10-28

Family

ID=57681784

Family Applications (2)

Application Number Title Priority Date Filing Date
MA053110A MA53110A (fr) 2015-12-10 2016-12-09 Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton
MA43409A MA43409B1 (fr) 2015-12-10 2016-12-09 Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA053110A MA53110A (fr) 2015-12-10 2016-12-09 Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton

Country Status (29)

Country Link
US (4) US10717745B2 (fr)
EP (2) EP3386991B1 (fr)
JP (2) JP6835846B2 (fr)
KR (1) KR102103395B1 (fr)
CN (2) CN113121562B (fr)
AR (1) AR107042A1 (fr)
AU (1) AU2016366541B2 (fr)
BR (1) BR112018011526B1 (fr)
CA (1) CA3007990C (fr)
CY (1) CY1123263T1 (fr)
DK (1) DK3386991T3 (fr)
EA (1) EA035168B1 (fr)
ES (1) ES2805835T3 (fr)
HR (1) HRP20201193T1 (fr)
HU (1) HUE049502T2 (fr)
IL (1) IL259863B (fr)
JO (1) JO3794B1 (fr)
LT (1) LT3386991T (fr)
MA (2) MA53110A (fr)
MD (1) MD3386991T2 (fr)
ME (1) ME03803B (fr)
MX (1) MX2018007075A (fr)
PL (1) PL3386991T3 (fr)
PT (1) PT3386991T (fr)
RS (1) RS60604B1 (fr)
SI (1) SI3386991T1 (fr)
TW (1) TWI729047B (fr)
UY (1) UY37015A (fr)
WO (1) WO2017100662A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018170220A1 (fr) * 2017-03-15 2018-09-20 Janssen Sciences Ireland Uc Procédés de formation sélective de liaison aryle- et hétéroaryle-azote
CN108164397B (zh) * 2018-01-18 2020-11-13 暨南大学 一类邻苯二酚衍生物及其制备方法
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
US20230094146A1 (en) * 2020-01-07 2023-03-30 Medshine Discovery Inc. Deuterated thienopyridine compound
EP4301365A1 (fr) 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Polythérapie utilisant un inhibiteur de malt1 et un inhibiteur de btk
KR20240019214A (ko) 2021-06-04 2024-02-14 얀센 파마슈티카 엔브이 브루톤 티로신 키나제의 억제제 및 이의 사용 방법
CN117642168A (zh) 2021-06-30 2024-03-01 詹森药业有限公司 布鲁顿酪氨酸激酶的抑制剂及其使用方法
CA3227033A1 (fr) 2021-08-09 2023-02-16 Eric Frederik ELDERING Compositions destinees a etre utilisees dans le traitement de malignites des lymphocytes b
WO2023156599A1 (fr) * 2022-02-18 2023-08-24 Janssen Pharmaceutica Nv Synthèse d'inhibiteurs de la tyrosine kinase de bruton

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
JP2008513463A (ja) 2004-09-15 2008-05-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チアゾロピリジンキナーゼ阻害剤
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
JP5305905B2 (ja) 2005-08-08 2013-10-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チアゾロピリミジンキナーゼ阻害剤
WO2007092879A2 (fr) * 2006-02-08 2007-08-16 Janssen Pharmaceutica, N.V. Inhibiteurs de kinase thiatriazaacénaphthylène-6-carbonirile substitués
PT2526933E (pt) 2006-09-22 2015-06-23 Pharmacyclics Inc Inibidores da tirosina-quinase de bruton
EP2365970B1 (fr) 2008-11-12 2018-03-21 Gilead Connecticut, Inc. Pyridazinones et leur utilisation comme inhibiteurs btk
JP5739334B2 (ja) * 2009-08-26 2015-06-24 武田薬品工業株式会社 縮合複素環誘導体およびその用途
WO2011133609A2 (fr) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Méthodes et nécessaires de prédiction de résultat thérapeutique associée à l'utilisation d'inhibiteurs de la btk
US20140249105A1 (en) 2011-07-25 2014-09-04 Diverchim Novel ceramide analogues, processes for preparing same and uses thereof
KR102311329B1 (ko) 2013-03-15 2021-10-14 얀센 파마슈티카 엔.브이. 약제를 제조하기 위한 방법 및 중간체
SI3080103T1 (sl) * 2013-12-11 2018-11-30 Biogen Ma Inc. Biarilne spojine, ki so uporabne za zdravljenje človeških bolezni na področju onkologije, nevrologije in imunologije
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103060A1 (fr) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibiteurs de tyrosine kinase de bruton et leurs procédés d'utilisation
WO2018103058A1 (fr) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibiteurs de tyrosine kinase de bruton et leurs procédés d'utilisation

Also Published As

Publication number Publication date
US10934310B2 (en) 2021-03-02
CA3007990A1 (fr) 2017-06-15
PT3386991T (pt) 2020-08-18
JP2018536686A (ja) 2018-12-13
MX2018007075A (es) 2018-11-09
AR107042A1 (es) 2018-03-14
HRP20201193T1 (hr) 2020-11-13
UY37015A (es) 2017-06-30
JP6835846B2 (ja) 2021-02-24
AU2016366541B2 (en) 2021-05-13
CN113121562B (zh) 2022-09-13
IL259863B (en) 2020-06-30
BR112018011526B1 (pt) 2024-02-27
AU2016366541A1 (en) 2018-05-31
JO3794B1 (ar) 2021-01-31
EA035168B1 (ru) 2020-05-08
KR102103395B1 (ko) 2020-04-23
MA53110A (fr) 2021-05-12
US20210101910A1 (en) 2021-04-08
WO2017100662A1 (fr) 2017-06-15
US20230097422A1 (en) 2023-03-30
EP3386991B1 (fr) 2020-06-03
EP3386991A1 (fr) 2018-10-17
CN108884106A (zh) 2018-11-23
JP2021073286A (ja) 2021-05-13
US11319329B2 (en) 2022-05-03
RS60604B1 (sr) 2020-08-31
TW201734021A (zh) 2017-10-01
ME03803B (fr) 2021-04-20
US20170283430A1 (en) 2017-10-05
HUE049502T2 (hu) 2020-09-28
MD3386991T2 (ro) 2020-11-30
LT3386991T (lt) 2020-08-25
EA201891378A1 (ru) 2018-12-28
PL3386991T3 (pl) 2021-03-08
CY1123263T1 (el) 2021-12-31
BR112018011526A2 (pt) 2018-11-21
KR20180093974A (ko) 2018-08-22
EP3719022A1 (fr) 2020-10-07
IL259863A (en) 2018-07-31
NZ742484A (en) 2021-09-24
CA3007990C (fr) 2024-01-02
JP7072690B2 (ja) 2022-05-20
SI3386991T1 (sl) 2020-08-31
US10717745B2 (en) 2020-07-21
CN113121562A (zh) 2021-07-16
TWI729047B (zh) 2021-06-01
DK3386991T3 (da) 2020-07-13
US20190276471A1 (en) 2019-09-12
ES2805835T3 (es) 2021-02-15

Similar Documents

Publication Publication Date Title
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
PH12018501463A1 (en) Pyrimidinyl tyrosine kinase inhibitors
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA37959A2 (fr) Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
MA41562B1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
EA201691514A1 (ru) Соединения
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
MA39317A1 (fr) Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA39337B1 (fr) Modulateurs de pyrazines de gpr6
ZA202001780B (en) Bezimidazole derivatives as adenosine receptor antagonists
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MX2019000884A (es) Formas de succinato y composiciones de inhibidores de la tirosina cinasa de bruton.
FR3078704B1 (fr) Derives d'isohexide et leurs utilisations
MA38523A1 (fr) Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigma
MA54520B1 (fr) Composés anticancéreux
EA201992728A1 (ru) Ингибиторы киназы и способы их применения